Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 1996 Nov;35(5 Pt 2):819-22.

Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis.

Author information

  • 1Division of Dermatology, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.

Abstract

Neutrophilic eccrine hidradenitis has been described in patients with acute myelogenous leukemia and other malignant diseases, usually during chemotherapy. We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine. Dapsone, 100 mg daily, was initiated 48 hours before the patient's third treatment with lomustine and was continued for 14 days. This regimen was successful in suppressing the reaction during the first course and three subsequent courses of lomustine.

PMID:
8912594
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk